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Introduction
!
This is the third of three guidelines (parts I – III)
within the framework of the European Federation
of Societies for Ultrasound inMedicine and Biology
(EFSUMB) Guidelines on Interventional Ultrasound
describing ultrasound (US)-guided percutaneous
diagnostic and therapeutic interventions of the ab-
domen. Part III deals with the indications and clin-
ical impact of US-guided therapeutic interventions
and gives evidence-based recommendations for
the safety and efficacy of these techniques using
the available evidence at the time of manuscript
preparation. It is complemented by guidelines on
general aspects of US-guided interventions (part I)
[1] and US-guided diagnostic interventions (part II)
[2]. In addition, EFSUMB also will publish guide-
lines on the use of diagnostic and therapeutic en-
doscopic ultrasound [3, 4] and ultrasound-guided
vascular interventions [5].
Methods of guideline development are descri-
bed in the introduction to the EFSUMB Guidelines
on Interventional Ultrasound [6]. Levels of evi-
dence (LoE) and grades of recommendations
(GoR) have been assigned according to the Oxford
Centre for Evidence-based Medicine criteria
(March 2009 edition) [http://www.cebm.net/ox-
ford-centre-evidence-based-medicine-levels-evi-
dence-march-2009].
Local ablative procedures
!
Introduction
Local ablative procedures play a key role in the
management of patients with malignancies, pri-
marily with hepatocellular carcinoma (HCC), but
also with metastases [7–10].
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Abstract
!
The third part of the European Federation of Socie-
ties for Ultrasound in Medicine and Biology
(EFSUMB) Guidelines on Interventional Ultrasound
assesses the evidence for ultrasound-guided and
assisted interventions in abdominal treatment
procedures. Recommendations for clinical practice
are presented covering indications, contraindica-
tions, safety and efficacy of the broad variety of
these techniques. In particular, drainage of absces-
ses and fluid collections, interventional tumor
ablation techniques, interventional treatment of
symptomatic cysts and echinococcosis, percuta-
neous transhepatic cholangiography and drainage,
percutaneous gastrostomy, urinary bladder drain-
age, and nephrostomy are addressed (short ver-
sion; a long version is published online).
Zusammenfassung
!
Der dritte Teil der Leitlinien der European Federa-
tion of Societies for Ultrasound in Medicine and
Biology (EFSUMB) zur interventionellen Sonografie
im Abdomen bewertet die Evidenz für transkutane
sonografisch gestützte und assistierte therapeuti-
sche Interventionen im Abdomen. Auf der Grund-
lage publizierter Daten werden zu Indikationen,
Kontraindikationen sowie zur sicheren und effi-
zienten Durchführung Empfehlungen für die kli-
nische Praxis gegeben. Berücksichtigung finden die
sonografisch geführte Drainage von Abszessen und
Flüssigkeitsansammlungen, Tumorablationstechni-
ken, transkutane Zystensklerosierung symptomati-
scher Zysten und der Echinokokkose, die perkutane
transhepatische Cholangiografie und Drainage, die
perkutane Gastrostomie, die Harnblasenpunktion
und Drainage sowie die Nephrostomie (Kurzver-
sion; eine Langversion ist online publiziert).
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Treatment intention
Local ablative procedures can be classified according to the treat-
ment intention as curative or palliative [11, 12].
Curative intention
Tumor ablation is usually performed with curative intent. This ap-
plies mainly to small HCCs (≤5 cm), as well as to colorectal liver
metastases [12–18]. The decision for local ablation over resection
should take into account data such as the patient’s age, co-morbid-
ities, normal parenchymal reserve and tumor distribution inside
the liver, as well as the risks for metachronous tumor growth, and
all these should be weighed against the invasiveness of the proce-
dure [11].
Recommendation 1
HCC ablation should be preferably performed with curative
intent (LoE 1a, GoR A). Strong consensus (100%).
Palliative strategy
The main indication for palliative treatment of liver tumors is
metastatic neuroendocrine tumor load. Other primary [19] and
secondary liver tumors may also be treated [11, 20–27].
Combined treatment options
With multiple liver metastases (commonly colorectal) not suita-
ble for surgical resection because of their number or location
(e. g., proximity of vascular or biliary structures), a combined ap-
proach should be considered [28].
Ablation in conjunction with resection is increasingly used as a
parenchyma-sparing curative strategy that combines effective ab-
lative treatment of small tumors with resection of large tumors,
for which ablation is less effective [29–36]. Similar concepts can
be applied to hepatocellular carcinoma (HCC) in a cirrhotic liver,
when extensive surgical sacrifice of the parenchyma must be a-
voided.
Recommendation 2
Ablation in conjunctionwith resection may be considered as a
parenchyma-sparing curative strategy (LoE 2a, GoR B). Strong
consensus (100%).
Hepatocellular carcinoma (HCC)
The treatment options for HCC in a cirrhotic liver are transplanta-
tion, surgical resection, local ablative therapies, transarterial che-
moembolization (TACE), radioembolizationwith Yttrium90 load-
ed beads (transarterial radioembolization) (TARE), and, in cases
of advanced disease, systemic therapy with sorafenib (Nexavar®).
Image-guided percutaneous ablation therapies, such as radiofre-
quency ablation (RFA) [37–39], percutaneous ethanol injection
(PEI) [40–42] andmicrowave ablation [43], have been performed
mainly with small HCCs, according to the Milan criteria [44].
These are potentially curative, minimally invasive, and repeatable
in case of recurrence [45].
Local ablative treatment techniques for HCC
Size of tumors
As a single RFA needle usually coagulates a region of about 2 cm
in diameter, potentially non-spherical (depending on the RF sys-
tem) multiple sequential insertions may be required to achieve a
safety margin.
To overcome this limitation, multi-needle systems have been in-
troduced for simultaneous ablations and stereotactically guided
RFA [46–49]. There is no accepted maximum tumor size that
can be ablated in a single session but the size is generally in the
4 to 5 cm range. The ablated zone should encompass the treated
tumor and a circumferential margin of 5–10mm around the tu-
mor [50].
Location of tumors
HCC tumors in a subcapsular location or adjacent to the gallblad-
der have a higher likelihood of incomplete ablation [51] or major
complications [52–54].
To reduce the number of complications, attention must be paid to
vulnerable structures close to the tumor or the ablation zone.
This applies to the porta hepatis, gallbladder, stomach, small in-
testine and colon, all of which are particularly sensitive to ther-
mal damage [55, 56]. In case of subdiaphragmatic lesions, pulmo-
nary, pleural or cardiac heat damage might occur, usually with
only minor clinical significance [57, 58].
Number of tumors
The maximum number of tumors that can be ablated in a single
procedure is not clearly defined, but ranges from 3 to 5 in most
centers [11]. Overall survival is best for patients with solitary tu-
mors, intermediate for those with 2 to 3 tumors, and worst for
those with ≥3 tumors [59].
Recommendation 3
Themaximum recommended diameter of HCC lesions treatable
with thermal ablation is generally considered below or equal to
5 cm, although optimal results are obtained in lesions < 3 cm
(LoE 2b, GoR B). Strong consensus (100%).
Recommendation 4
The ablation zone should aim to extend at least 5mm beyond
the visible borders (LoE 3a, GoR B). Strong consensus (100%).
Recommendation 5
In lesions close to large vessels and heat-sensitive structures,
alternative or additional techniques should be considered
(LoE 3a, GoR B). Strong consensus (100%).
Recommendation 6
Three to five HCCs are the recommended maximum number
of lesions in a single session that allows percutaneous ablation
with curative intent (LoE 2a, GoR B). Strong consensus (100%).
RFA versus surgical resection in small HCCs
There is inconclusive evidence as towhether RFA is as effective as
surgical resection as the first-line treatment for patients with
small, solitary HCCs [50, 51, 53–56, 60–63]. A systematic review
of 8000 patients [64] with a current Cochrane analysis [65] re-
ported uncertainty regarding the question of the impact of RFA
versus surgery. However, a more recent meta-analysis, published
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after the Cochrane analysis [66], showed that there were differ-
ences in age and liver function between patients with early HCC
submitted to either RFA or resection. When the analysis was cor-
rected for these parameters, no survival differences were ob-
served between RFA and surgery in single HCCs <2 cm or 2–3
HCC tumors < 3 cm, whereas surgery resulted in a longer survival
in the case of single HCCs measuring 2–5 cm [66]. Mortality and
morbidity rates of RFA have been reported to be 0–1.5% and
0.9–7.9 %, respectively [67–72].
Percutaneous ethanol injection (PEI)
PEI was the first ablative procedure, initially reported in the early
1980 s [40, 41, 73].
The procedure is inexpensive and safe, with low mortality and
morbidity (0–3.2 % and 0–0.4%, respectively) [74–76]. Even
though RFA has replaced PEI [38, 77, 78], PEI can be offered in
small HCCs, mainly those for which RFA is not feasible due to tu-
mor location.
RFA versus PEI
Randomized controlled trials comparing RFA with PEI demon-
strate that RFA is superior to ethanol injection in terms of treat-
ment response, number of sessions, recurrences, and overall sur-
vival [77–83] as further supported bymeta-analyses [65, 82, 84].
The efficacy of the methods is similar for tumors ≤2cm [38, 77, 78,
85]. Meta-analyses, including randomized controlled trials (RCTs),
confirmed that treatment with RFA offers a survival benefit as
compared to PEI in tumors > 2 cm [82–84, 86, 87]. RFA has a slight-
ly higher rate of major complications (4%; 95% CI, 1.8–6.4%) as
compared to PEI (2.7%; 95% CI, 0.4–5.1%) [52, 79, 81, 87]. The
best results obtained in series of HCC patients treated by RFA
provided 5-year survival rates of 40–70% or higher in select
groups of patients [47, 67, 88]. The best outcomes have been re-
ported in Child–Pugh A patients with small (< 2 cm) single tumors
[70, 89]. Independent predictors of survival with RFA are initial
complete response, Child–Pugh score, number or size of nodules,
and baseline alpha-fetoprotein levels [90].
Other procedures
Percutaneous microwave ablation (MWA) was introduced into
clinical practice in the 1990 s [43, 91–97].
Selection of ablation technique
With PEI, local response is related to tumor size. PEI has yielded
very favorable results for small encapsulated HCCs (< 2 cm) [12,
73]. HCC encapsulation by a cirrhotic liver prevents satellite no-
dules from being reached, leading to higher rates of local recur-
rence in comparison to RFA [98–101]).
Recommendation 7
Percutaneous ethanol injection with curative intent is an al-
ternative to thermal ablation in encapsulated HCCs <20mm
(LoE 2a, GoR B). Broad agreement (95%).
Recommendation 8
Percutaneous ethanol injection can be an alternative in case of
contraindications to thermal ablation (LoE 3b, GoR B). Broad
agreement (79%).
Selection of imaging modality (ultrasound, CT, MRI)
US is the first-line imaging modality for local ablative procedures
in the liver. CT guidance can be an alternative, particularly when
US guidance is not feasible anatomically or with US imaging of
occult lesions [102, 103]. MRI guidance is possible but with lim-
ited availability and major costs. Local expertise and personal ex-
perience determine the modality of choice. Contrast-enhanced
imaging must be available during the interventional procedure
to confirm the completeness of necrosis. Fusion imaging is an al-
ternative technique that can be used for the guidance of the pro-
cedure.
Planning and monitoring ablation treatment
Imaging plays an important role before, during and after ablation
procedures. Assessment of tissue perfusion is crucial to differ-
entiate necrotic areas from viable residual tumor. With US-and
CT-guided RFA, this requires evaluation with contrast-enhanced
imaging during and immediately after ablation. Contrast-en-
hanced ultrasound (CEUS) can provide important information
for assessment during and immediately after ablation [104, 105]:
▶ assessment of the lesions to be treated by ablation (number,
size, degree and homogeneity of lesion enhancement, pres-
ence of feeding vessels, to define the eligibility for treatment
and the best ablation strategy)
▶ depiction of previously undetectable lesions with the support
of fusion imaging, enabling needle/probe guidance to occult
lesions
▶ detection of viable tumor persistence following loco-regional
treatment [50]
CEUS is the most effective method to define local recurrence in a
treated nodule because of its real-time capability, the intra-vas-
cular characteristic of the contrast agent and the near-total dif-
ferentiation between the displayed contrast and background in-
formation of current imaging methods [8]. CT and MRI provide
better overviews of the liver and adjacent organs, which are nec-
essary for pretreatment staging and useful to detect distant intra-
and extra-hepatic tumor recurrence.
Complications
Studies have established that RFA is a low-risk procedure [106–
109], with amortality of 0.1–0.8% and few adverse events. Major
complications occur in 2.2–11% of RFA-treated patients [72, 106,
110–112]. Bleeding, infection, arteriovenous fistula formation,
bile duct damage, and tumor seeding are possible complications
of local ablative therapy [11, 12, 18, 113].
Thermal track ablation can potentially reduce the likelihood of
tumor seeding in HCC ablation to below 1% [114–117].
Recommendation 9
A multidisciplinary approach to assess patients with HCC in
liver cirrhosis for possible transplantation is recommended
prior to alternative treatments (LoE 5, GoR D). Strong consen-
sus (100%).
Recommendation 10
RFA with curative intent is an alternative, more cost-effective
technique in comparison to surgery in early HCC BCLC-0 (HCC
<2 cm) (LoE 2a, GoR B). Strong consensus (100%).
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Recommendation 11
RFA with curative intent should be considered as a second-line
treatment in single HCCs 2–5 cm in Child-Pugh A patients, after
the patient has been evaluated for surgical resection (LoE 2b,
GoR B). Strong consensus (100%).
Recommendation 12
RFAwith curative intent should be considered as the first-line
treatment in Child-Pugh B patients with single HCCs <5 cm or
in patients with 2 or 3 HCCs <3 cm (LoE 2b, GoR B). Strong
consensus (100%).
Recommendation 13
Solitary HCCs >3 cm not suitable for surgery should be consid-
ered for combined loco-regional treatments (LoE 4, GoR C).
Broad agreement (95%).
Colorectal cancer liver metastases
It is estimated that 50–60% of patients with colorectal cancer
(CRC) will develop liver metastases [118]. The most successful
treatment for hepatic metastases is surgical resection [9, 10, 31,
59, 119–125]. However, approximately 50–70% of these patients
will develop recurrence [126].
Local ablative procedures with curative intent have a role in the
management of CRC liver metastases [9, 10]. Depending on the
size of the lesions, RFA may be performed alone or combined with
resection [127]. Several studies have demonstrated that RFA
achieved permanent local ablation of liver metastases and a 5-
year survival of 24% to 43% [128–132]. These results are compar-
able to surgery [31, 59, 119–125]. Local recurrence occurs more
frequently after ablation than with resection [9, 10, 133].
Two meta-analyses confirmed that surgery is superior to RFA
with regard to survival outcomes in patients with resectable
CRC liver metastases [134, 135]. The first RCT on the efficacy of
RFA combined with chemotherapy versus chemotherapy alone
was underpowered; RFA plus systemic treatment resulted in sig-
nificantly longer progression-free survival (PFS) compared with
chemotherapy alone [136].
Recommendation 14
Percutaneous thermal ablation with curative intent is a sec-
ond-line alternative to surgery in patients with colorectal liver
metastases (LoE 2a, GoR B). Strong consensus (100%).
Recommendation 15
The maximum diameter of metastatic lesions treatable with
thermal ablation is generally considered ≤4 cm, although bet-
ter results are obtained in lesions <3 cm (LoE 5, GoR D). Strong
consensus (100%).
Recommendation 16
The ablation zone should aim to extend at least 10mmbeyond
the visible borders (LoE 5, GoR D). Broad agreement (94%).
Other liver metastases
Percutaneous thermal ablation or PEI may be a therapeutic op-
tion for neuroendocrine liver metastases [23, 24].
Renal malignancies treated with local ablative therapy
Introduction
Possible treatment options for renal cell carcinoma (RCC) are
[137]:
▶ Surgery, either nephrectomy or nephron-sparing (open or
laparoscopic)
▶ Local ablative procedures (percutaneous or laparoscopic)
▶ cryoablation
▶ RFA
▶ MWA
▶ Active surveillance
Small masses
Standard therapy for small RCCs is nephron-sparing surgery. Lo-
cal ablative techniques have evolved into alternative procedures,
showing excellent results [138].
Tumors < 4 cm in diameter are ideal candidates for ablative tech-
niques. The volume to be treated should include a 5–10mm safe-
ty margin [139]. Most tumors <3 cm can be treated in a single ab-
lation session. Tumors between 3–4 cm in diameter can also be
successfully treated, although multiple ablation sessions may be
required [140–148].
Recommendation 17
Patients with RCCs <3 cm with significant surgical risk or re-
quirement for nephron-sparing strategy should be considered
for local ablative therapy (LoE 2b, GoR B). Strong consensus
(100%).
RCTs comparing surgery and local ablative therapy have not been
performed [137, 149]. Cancer-specific survival is similar for both
methods [150, 151]. The European and American Urological As-
sociations recommend thermal ablation as a treatment option
for patients with a T1 renal mass [152].
Local recurrence-free survival following image-guided tumor ab-
lation is 87% [153]. The local recurrence of percutaneously per-
formed RFA is estimated at 2.5–14% [154]. Cancer-specific survi-
val of patients treated with RFA is comparable to patients treated
with surgery [142, 152, 155]. Both cryotherapy and RFA had a
higher risk of recurrence compared to partial nephrectomy
[156], but re-intervention is straightforward [142].
The rate of major complications for cryotherapy is 5%, which is
lower than for surgery [152], the most common complication
being hemorrhage [213] with 2% developing distant metastases
[152, 155]. Post-procedural ureteric strictures have also been
documented [152]. Cryotherapy is preferred over RFA in central tu-
mors in contact with the renal hilum or the ureter [157].
Recommendation 18
RCC histology should be obtained prior to ablation (LoE 4, GoR
C). Broad agreement (81%).
CEUS can be used for surveillance after RFA of RCCs in order to de-
tect local recurrence and to assess for liver metastases [158]. CT of
the thorax and abdomen is necessary to excludemetachronous ex-
trahepatic metastases. No RCTs have been performed [159–161].
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Recommendation 19
Contrast-enhanced ultrasound or CT or MRI should be per-
formed in the follow-up after RCC ablation, unless contraindi-
cated (LoE 4, GoR C). Strong consensus (100%).
Abscess drainage
!
US-guided percutaneous drainage of abdominal abscesses is a
well-established interventional procedure first described in 1974
[162] and is currently the first-line treatment approach for abdom-
inal abscesses.
Definition and classification
Differentiation between phlegmonous inflammation and absces-
ses is of importance for treatment guidance. An abscess is a pus-
containing confined collection, most often caused by bacteria. To
be termed an abscess, the fluid has to be viscous and surrounded
by an inflammatory wall that develops as a result of effective host
defense [163].
Recommendation 20
Phlegmonous infections and small abscesses should be treat-
ed with antibiotics and require no drainage (LoE 5, GoR D).
Strong consensus (100%).
Postoperative fluid collection
Fluid collections present on postoperative imaging, localized or
generalized (“free fluid”), are common and nonspecific which
may represent different pathological entities such as hematoma,
exudate, seroma, biloma, lymphocele or an abscess. Fluid seen on
imaging is often not characteristic; any patient with a clinical sus-
picion of an abdominal abscess should have a diagnostic aspiration
to guide further management. Sterile fluid collections can become
infected postoperatively, requiring diagnostic aspiration and even-
tually therapeutic drainage.
Ultrasound (US)
US imaging is often the initial modality used in abscess delinea-
tion as it allows dynamic evaluation and real-time guidance of
needling. Depending on the contents, an abscess can be anechoic,
hypoechoic and even hyperechoic. CEUS can be helpful in differ-
entiating vascularized from avascular areas [164, 165].
CT is indicated in technically limited US examinations or incon-
clusive results.
Diagnostic aspiration
A US-guided diagnostic puncture of a fluid collection with a fine
needle or a larger needle (depending on the viscosity) can distin-
guish an abscess from a non-infected fluid collection.
Recommendation 21
Diagnostic aspiration of a suspected infected fluid collection is
recommended (LoE 5, GoR D). Strong consensus (100%).
Puncture and drainage
Catheter drainage versus needle aspiration
A meta-analysis of 5 RCTs comparing catheter drainage and re-
peated needle aspirations of liver abscesses demonstrated cathe-
ter drainage to be more effective, with higher success and shorter
time to achieve clinical improvement [166]. Studies of abdominal
abscesses of various etiologies have shown good results with re-
peated needle aspiration in simple abscesses < 5 cm. In larger ab-
scesses catheter drainage performed better than repeat needle
aspiration [167–171].
Recommendation 22
Abscesses less than 5 cm in diameter can be treated with nee-
dle aspiration (LoE 2b; GoR B). Strong consensus (100%).
Recommendation 23
Catheter drainage is more effective than needle aspiration in
abscesses larger than 5 cm in diameter (LoE 1a, GoR A). Broad
agreement (89%).
Small or large catheters
No difference in outcome was seen in a study of intra-abdominal
abscesses treated with 7F pigtail catheters and 14F sump drain ca-
theters [172]. Currently large catheters (> 10F) should be reserved
for complex abscesses containing thick pus and debris.
Recommendation 24
Catheters of 7–10F in size are recommended for the treat-
ment of most abscesses, regardless of abscess dimensions
(LoE 4, GoR C). Broad agreement (90%).
Recommendation 25
Large catheters (> 10F) should be reserved for complex absces-
ses with thick contents (LoE 5, GoR D). Broad agreement
(90%).
Catheter introduction techniques: Trocar versus Seldinger
Two techniques are used for the insertion of a drainage catheter:
the trocar (one-step) technique and the Seldinger (two-step) tech-
nique. Both have advantages and disadvantages and can be per-
formed with either a free-hand or needle-guided technique, de-
pending on the preference and experience of the operator.
Recommendation 26
The trocar technique is suitable in most circumstances using
catheters ≤10 F (LoE 5, GoR D). Broad agreement (93%).
Recommendation 27
The Seldinger technique is recommendedwhen access is diffi-
cult, for large catheters, and for catheter replacement (LoE 5,
GoR D). Broad agreement (86%).
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Single versus double lumen
Double lumen catheters are not recommended since they com-
bine the negative features of large diameters and relatively small
lumens.
Recommendation 28
Double lumen catheters are not recommended (LoE 5, GoR D).
Broad agreement (94%).
Abscess cavity extension and complexity, fistula, and
contrast injection (X-ray, CEUS)
Treatment planning requires careful assessment of the size, shape,
content and extent of the abscess, including identification of asso-
ciated fistulas. Fistulography (or abscessography, sinography) with
intracavitary injection of iodinated contrast media under CT or
fluoroscopic guidance has been the recommended technique. Di-
rect injection of US contrast agent through the needle or catheter
has been reported to facilitate confirmation of correct needle or
catheter position and allows evaluation of any communication be-
tween cavities in complex abscesses at the bedside [173–175].
Recommendation 29
Intracavitary CEUS may add value regarding needle and cath-
eter position, cavity morphology and presence of fistulas (LoE
4, GoR C). Strong consensus (100%).
Specific organs and locations
Liver abscess
Pyogenic liver abscesses are often the result of biliary obstruction
caused by benign or malignant diseases with consequent cholan-
gitis. For percutaneous drainage, a transhepatic access route is
preferred for direct puncture to avoid spillage of pus into the peri-
toneal cavity. Small amebic abscesses generally respond to con-
servative treatment and do not require drainage, but large amebic
abscesses may need drainage [176].
Recommendation 30
The origin of liver abscesses should be investigated to search for
an underlying cause (LoE 5, GoR D). Strong consensus (100%).
Recommendation 31
A transhepatic access route is recommended for the percuta-
neous drainage of hepatic abscesses (LoE 5, GoR D). Strong con-
sensus (100%).
Splenic abscess
Splenic abscesses are rare, except in immunocompromised pa-
tients. Splenic puncture or biopsy is relatively safe as documen-
ted in a meta-analysis [177].
Recommendation 32
Percutaneous splenic abscess drainage should be the first-line
treatment and surgery should be performed in the case of
treatment failure (LoE 4, GoR C). Broad agreement (89%).
Pancreatic abscess
Percutaneous drainage of pancreatic abscesses is often prolonged
and may require multiple catheters. The percutaneous approach
offers quick access for severely ill patients. As a second stage pro-
cedure, conversion to internal drainagewith an endosonographic
approach should be considered.
Recommendation 33
Pancreatic abscess management is complex and often pro-
longed. Drainage procedures guided by transcutaneous or en-
doscopic ultrasound (EUS) should be considered (LoE 4, GoR
C). Broad agreement (89%).
Enteric abscess
Abscesses are frequent complications of Crohn´s disease, diverticu-
litis and appendicitis. In Crohn´s disease, there is no study compar-
ing percutaneous and surgical drainage of abscesses. Percutaneous
drainage of Crohn’s-related abscesses has a high success rate, dem-
onstrated in several studies and is the first-line treatment [178,
179]. With early percutaneous drainage, (non-elective) surgery
can often be avoided (14–85% of patients) [179–183].
Abscesses can be detected in 15% of patients with acute diverti-
culitis [184, 185]. Antibiotics successfully treat smaller abscesses
(< 3 cm) [184, 186, 187], but larger abscesses (>3 cm) require per-
cutaneous drainage [188, 189]. Peri-appendicular abscesses can
occur either as a result of rupture of an infected appendix or
post-operatively.
It is generally accepted that a peri-appendicular abscess will re-
spond to percutaneous drainage. Leakage of enteric contents at an
anastomosis may lead to abscess formation, which most often re-
quires reconstructive surgery. Sometimes, a non-surgical approach
is preferred with usage of long-term percutaneous drainage with
large catheters.
Recommendation 34
Abscesses in Crohn´s disease, diverticulitis and appendicitis
may benefit from percutaneous drainage as the first-line
strategy (LoE 4, GoR C). Broad agreement (89%).
Abscess in the lower abdomen and pelvis
For deep pelvic abscesses, alternative puncture routes are avail-
able. Transrectal, transvaginal, transperineal and transgluteal ac-
cesses have all been shown to be useful and safe [169, 190–192].
Recommendation 35
US-guided drainage by transrectal, transperineal or transvagi-
nal access is associated with a low risk of complications and
should be considered for deep pelvic abscesses (LoE 4, GoR
C). Strong consensus (100%).
Recommendation 36
Use of intracavitary fibrinolytics is not routinely recommen-
ded (LoE 5, GoR D). Broad agreement (94%).
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Ultrasound-guided paracentesis
!
Background
Paracentesis is performed either as a diagnostic or as a therapeu-
tic procedure, in the presence of ascites or suspected bacterial
peritonitis. Therapeutic paracentesis provides almost immediate
symptomatic relief and is usually well tolerated.
Technical issues
Ascites drainage is usually easily and safely performed by insert-
ing a 14–18 gauge needle (including paracentesis-specific devi-
ces) or as a one-step catheter under US guidance. Catheters can
be pig-tail, they can have an internal string for internal loop fixa-
tion, or an internal balloon fixation can be used. A small bore
catheter (between 5F and 7F) is usually adequate.
US guidance offers real-time imaging of the needle tip and sur-
roundings during the procedure, making it safe and effective. In
most instances, US assistance (i. e., US utilized to select the best
access point prior to blind needle insertion) is as safe as US gui-
dance [193].
Complications
Paracentesis is considered a safe procedure, carrying a 1% risk of
overall complications, which include leakage of ascitic fluid, local
infection, abdominal wall hematomas, intraperitoneal hemor-
rhage, and intestinal perforation [194]. It is recommended to fol-
low strict antiseptic practices in all patients [195]. Ultrasound
guidance can reduce the risk of complications after paracentesis
[193, 196].
Recommendation 37
Ultrasound-guided or assisted paracentesis is a low-risk and
effective procedure (LoE 4, GoR C). Strong consensus (100%).
Specific considerations
Cirrhosis
Ascites is the most common complication of cirrhosis leading to
hospital admission.
Albumin administration
Large-volume paracentesis (> 5 L) is generally an effective and
safe procedure, but it does carry a risk of “postparacentesis circu-
latory dysfunction” (PCD).
Recommendation 38
Administration of albumin is mandatory in large-volume (> 5
liters) paracentesis (LoE 1a, GoR A). Strong consensus (100%).
Recommendation 39
There are no established preprocedural threshold coagulation
levels that preclude paracentesis (LoE 5, GoR D). Broad agree-
ment (94%).
Palliative paracentesis for malignant ascites
Malignant ascites accounts for around 10% of cases and occurs
with a variety of neoplasms [197]. Large amounts of ascites can
cause increased abdominal pressurewith pain, dyspnea, loss of ap-
petite, nausea, and reduced mobility. Long-term paracentesis is in-
dicated for patients with symptoms of increased intraabdominal
pressure caused by recurring malignant ascites despite repeated
paracentesis.
Recommendation 40
Permanent catheter drainage should be considered for term-
inally ill patients with refractory ascites (LoE 4, GoR C). Broad
agreement (94%).
Sclerotherapy of non-parasitic cysts
!
Hepatic cysts
Hepatic cysts have a prevalence of 2.5–7%. Most are asympto-
matic and do not need treatment [198]. Percutaneous treatment,
consisting of aspiration of cystic fluid followed by injection of a
sclerosing agent, is usually performed with US guidance, as a
minimally invasive option for large or symptomatic cysts.
Indications
Large cysts (> 6–10 cm), which are symptomatic (pain or infec-
ted) or causing space-occupying effects (abdominal distension,
obstructive jaundice or both), require treatment. Other less es-
tablished indications include symptomatic small sub-capsular
cysts located at sites exposed to mechanical stress (beneath the
ribs or sternum) [199]. In polycystic liver disease, any cysts may
be treated if causing symptoms or to avoid complications (e. g.,
rupture, bleeding, infection) [200–205].
Recommendation 41
With symptomatic or compressive hepatic cysts, percutaneous
sclerotherapy or surgery should be considered (LoE 4, GoR C).
Strong consensus (96%).
Contraindications
Caution is required when treating hydatid cysts; the nature of a
cyst may not be known prior to aspiration [199]. A relative con-
traindication is hemorrhagic cysts [206] although they can be
treated with similar results once infection or malignancy has
been excluded [202]. Ascites and planned liver transplantation
are other relative contraindications.
Multidisciplinary decision making
Multidisciplinary decision (gastroenterologists, surgeons, inter-
ventional radiologists) for the procedure is mandatory as other
options include open surgery and laparoscopic deroofing which
are effective treatments. These treatments are associated with
substantial morbidity and mortality and require expertise [207,
208]. Percutaneous treatments have similar efficacy, allowing
surgery to be reserved for complicated cases or if percutaneous
sclerotherapy fails [201, 209].
Sclerotherapy versus surgery (fenestration)
No randomized prospective study comparing fenestration and
sclerotherapy has been published. In most centers, sclerotherapy
is attempted first as a noninvasive option, and laparoscopic fe-
nestration is indicated in refractory cases [209].
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Recommendation 42
Percutaneous ethanol sclerotherapy is a good alternative to la-
paroscopic deroofing with similar efficacy and lower compli-
cation rates (LoE 4, GoR C). Strong consensus (96%).
Prognosis
The majority of patients who undergo percutaneous sclerotherapy
are symptomatically improved immediately following the proce-
dure, but only 20% will have partial or full regression of the domi-
nant and symptomatic cyst [208]. In polycystic liver disease both
sclerotherapy and surgery are disappointing (77–100% recur-
rence rate) [9].
Materials and technical issues
The treatment consists of evacuation of the cystic contents (either
by aspiration or drainage via a catheter) followed by sclerotherapy
of the inner epithelium using standard agents (ethanol, polidoca-
nol, tetracycline chloride, minocycline chloride, hypertonic saline
solution and ethanolamine oleate) [210–214]. A radiopaque con-
trast medium or US contrast agent should be instilled into the cyst
to exclude a connection with the biliary tree [215]. If contrast
medium enters the bile ducts, sclerotherapy is contraindicated.
Ethanol sclerotherapy
Ethanol (95–98% concentration) is most commonly used for
sclerotherapy of hepatic cysts [216–218]. Single or multiple ses-
sions may be needed with evacuation of the fluid content per-
formed using 6–8F catheters or a Chiba needle (18–20 gauge)
[216–218]. After ethanol sclerotherapy, an 80–100% reduction
of cyst volume may be achieved [198, 201, 210, 216, 218, 219].
The main complications during ethanol sclerotherapy are pain,
ethanol-induced fever or hyperthermia, intoxication, intra-cystic
bleeding and iatrogenic pleurisy or peritonitis [202, 211].
Recommendation 43
With percutaneous ethanol sclerotherapy of large liver cysts,
the use of small catheters instead of needles should be consid-
ered to achieve a longer ethanol exposure time (LoE 4, GoR C).
Broad agreement (95%).
Sclerotherapy using other substances
Several other substances with better safety profiles, ease of use
and low cost have been tested with good results and few compli-
cations [210–214]. Polidocanol 1–3% (aethoxysklerol) may be
preferred for its local anesthetic properties (it is less painful
than alcohol) and its slight bactericidal activity [199].
Recommendation 44
Percutaneous sclerotherapy using other substances is an alter-
native to ethanol (LoE 4, GoR C). Broad agreement (90%).
Ultrasonographic follow-up
In polidocanol therapy maximum volume reduction occurred 1
year after the procedure [215]. Follow-up examinations may
only be necessary in symptomatic patients.
Renal cysts
Indications
Simple renal cysts are mostly asymptomatic and do not require
treatment. In 2–4% the cyst may become symptomatic because
it enlarges or develops complications such as hemorrhage, infec-
tion, rupture or compression [220]. Cysts that develop adjacent to
the renal hilum may obstruct the urinary tract [221]. US-guided
cyst aspiration with or without sclerosing therapy is a minimally
invasive, simple, safe and low-cost procedure [221].
Recommendation 45
Symptomatic simple renal cysts should be considered for treat-
ment. (LoE 4, GoR C). Broad agreement (94%).
Multidisciplinary decision making
A multidisciplinary decision regarding procedure choice is re-
commended as surgical excision via open, percutaneous, laparo-
scopic or robotic surgery is effective but more invasive. Laparo-
scopic deroofing achieves better results than percutaneous
sclerotherapy (PS) [220, 221].
Recommendation 46
The decision on treatment modality should consider that per-
cutaneous sclerotherapy is less invasive and associated with
lower risks than laparoscopic deroofing, but has lower efficacy
(LoE 2b, GoR B). Broad agreement (88%).
Materials and technical aspects
A variety of substances are used for sclerotherapy of the cystic
wall [214, 222–231] as described for liver cysts.
Simple cyst drainage without sclerotherapy
After simple aspiration, the recurrence ranges from 30–80%
[171, 232].
Recommendation 47
Simple aspiration should not be used in the treatment of renal
cysts because recurrence is frequent (LoE 4, GoR C). Broad
agreement (93%).
Ethanol sclerotherapy
The most common sclerotherapy agent for renal cysts is ethanol
[227–231]. A concentration of 95–99% destroys the secreting
cells of the cyst wall without affecting the renal parenchyma
[220]. Single or multiple sessions have been used, with better re-
sults but with higher complications for multiple sessions [221,
228–233].
The main complications that may occur during ethanol sclero-
therapy are pain, fever, and systemic reactions [220].
Recommendation 48
Multiple sessions and/or prolonged drainage should be used to
reduce recurrence in symptomatic large renal cysts treated with
ethanol sclerotherapy (LoE 4, GoR B). Broad agreement (87%).
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Ultrasonographic follow-up
Follow-up examinations may only be necessary in symptomatic
patients.
Abdominal echinococcal cysts, puncture, aspiration,
injection and re-aspiration (PAIR)
!
Introduction
Echinococcosis is a chronic, complex and neglected zoonosis with
widespread global distribution. 70% of cases of cystic echinococ-
cosis (CE) are located in the liver [234]. US has an important role
in the diagnosis, treatment and follow-up of abdominal CE and is
established in the interventional treatment of abdominal CE
[235, 236].
Classification
The WHO echinococcal cyst classification [237, 238] is US-based
and was introduced to guide treatment options and to predict
prognosis [239]. Type CE1 and CE2 are the typical active cysts.
Type CE1 is unilocular, whereas CE2 is multilocular with daugh-
ter cysts. The Gharbi classification is still widely used [240].
Diagnosis and differential diagnosis
Imaging
US is the imaging modality most appropriate for diagnosis and
differential diagnosis [238], while US guidance is usually used
for intervention [241, 242].
Serological tests
Serological tests for echinococcosis should be obtained, where
available, before the procedure [243, 244].
PAIR indication
PAIR is most appropriate for CE1 and CE3a according to the WHO
classification (Gharbi type I and II cysts) [244, 245].
Relative contraindications
Hydatid cysts with multiple daughter cysts and solid compo-
nents (Gharbi Type III-IV and WHO CE2-CE3b) are not suitable
for PAIR [236, 245, 246]. It is reported that aggressive percuta-
neous evacuation for these complex cysts is useful, but not wide-
ly accepted.
Pretreatment procedures
Aswith any interventional procedure, the patient should be care-
fully evaluated before the PAIR procedure. Albendazole should be
started one week (or at least one day) prior to the procedure for
prophylaxis against abdominal contamination [247], and there-
after continued for at least one month [236, 248].
Procedure, puncture and drainage
The procedure consists of puncture, aspiration, injection and re-as-
piration [239, 249, 250] using a 20-gauge fine needle [251, 252].
Outcome
RCTs showed PAIR to be superior to albendazole alone [253] and
to surgical treatment [239, 254]. PAIR combined with albenda-
zole was more effective than surgery and was associated with a
lower rate of adverse events and a shorter hospital stay. Retro-
spective studies favor PAIR over surgery in Gharbi type I and II
cysts and found surgical treatment most appropriate in the other
Gharbi types [249, 255].
A meta-analysis reported severe adverse events (anaphylaxis,
cyst infection, abscess, sepsis, biliary fistula) in 7.9% of patients
treated with PAIR plus albendazole [256].
Recommendation 49
US-guided PAIR is the most appropriate treatment for WHO
CE1 and CE3a abdominal hydatid cysts (LoE 2b, GoR B). Strong
consensus (100%).
Recommendation 50
PAIR should always be accompanied by measures to manage
possible anaphylaxis (LoE 5, GoR D). Broad agreement (93%).
Recommendation 51
Albendazole should be started prior to PAIR (LoE 2b, GoR B).
Strong consensus (100%).
Percutaneous transhepatic cholangiodrainage (PTCD)
!
Introduction
Percutaneous transhepatic cholangiography and drainage (PTCD)
is a commonly used procedure for the diagnosis and treatment of
benign and malignant biliary diseases [257, 258]. PTCD also al-
lows therapeutic interventions, such as placement of a stent
across amalignant stricture, dilatation of benign biliary strictures
and extraction of biliary tract stones [259].
Endoscopic retrograde cholangiography versus PTCD
versus endoscopic ultrasound-guided cholangiodrainage
Endoscopic retrograde cholangiography (ERC) is the method of
choice for patients with indications for (therapeutic) biliary access
[260, 261]. The following surgically altered anatomical situations
have a high likelihood for ERC failure: Roux-en-Y with gastric by-
pass, Kausch-Whipple resection, pylorus-preserving Whipple re-
section, Roux-en-Y with hepaticojejunostomy, choledochojeju-
nostomy, and pancreaticojejunostomy [262].
Alternative methods are PTCD, EUS-guided interventions (EUS
cholangiodrainage, EUS-CD) [192] and balloon-assisted entero-
scopy (BAE).
Special problems
Ultrasound guidance versus fluoroscopic guidance
A blind percutaneous puncture of peripherally located intrahepa-
tic bile ducts has limitations especially with non-dilated bile ducts
[263, 264]. Real-time imaging with US is useful for the guidance of
PTCD (US-PTCD), especially in patients with non-dilated ducts and
for left-sided PTCD [265–267]. Fluoroscopy delivers significant ir-
radiation both to the patient and to the interventional team. The
“As Low As Reasonably Achievable” (ALARA) principle should be
applied [268].
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Recommendation 52
For initial puncture in PTCD ultrasound guidance should be
considered (LoE 4, GoR C). Strong consensus (100%).
Percutaneous cholecystostomy
!
Introduction
Acute calculous cholecystitis (ACC) is a common cause of acute
surgical admission. Early cholecystectomy (CCE) is a widely ac-
cepted method of treatment [269]. Laparoscopic cholecystect-
omy (LCCE) in acute cases has minimal morbidity [270]. In high-
risk patients morbidity and mortality increase to 14–46% [271].
Alternatively, percutaneous cholecystostomy (PC) is a bridging
process, especially in otherwise healthy patients (e. g. ASA I and
II) who are severely septic and may become fit in due course for
semi-elective surgery [272].
Clinical efficacy
A meta-analysis of 53 studies (n =1918 patients) reported suc-
cessful PC for 85.6 % of patients. The procedure-related mortality
rate of PC was 0.4% [273].
Evaluation of US-guided percutaneous cholecystostomy (USPC)
for patients with acute acalculous cholecystitis (AAC) is more dif-
ficult because it is normally a complication of serious medical
and surgical illnesses [274, 275]. A study compared clinical effica-
cy and adverse events of PC and CCE in a large group of severely ill
patients with AAC and showed PC to be a safe and cost-effective
bridging treatment strategy, with perioperative outcomes super-
ior to those of open CCE. Compared with open or laparascopic
CCE (n=1021), PC (n=704) was superior in terms of morbidity,
intensive-care unit admissions, length of hospital stay, and costs
[276]. Two studies showed that in seriously ill patients with AAC,
PC is an effective procedure and may be regarded as a definite
treatment option in the majority of patients [277, 278].
Data is limitedwith respect to the duration of gallbladder drainage.
Before removal of the drain, laboratory and clinical data should
confirm resolution of sepsis [279]. Patients should be re-evaluated
following recovery to assess fitness for elective surgery. Cholecys-
titis recurrence of 10–30% is reported, and should be weighed
against the mortality and morbidity risk in the individual patient.
Recommendation 53
Percutaneous ultrasound-guided gallbladder drainage may be
considered in patients with acute calculous cholecystitis as-
sessed to be unfit for surgery (LoE 3b, GoR B). Strong consen-
sus (100%).
Recommendation 54
In patients with acute acalculous cholecystitis unfit for sur-
gery, percutaneous ultrasound-guided gallbladder drainage
should be considered after diagnostic puncture (LoE 2c, GoR
B). Strong consensus (100%).
Drainage route
The transhepatic route has advantages regarding tract formation
and the avoiding of peritonitis [280, 281]. The transperitoneal ap-
proach has been reported to be similar in relation to complica-
tions, but formation of a mature tract without leakage as a pre-
condition for catheter removal is significantly delayed compared
with the transhepatic approach [280, 282, 283]. EUS-guided
transmural gallbladder drainagemay be performed as an alterna-
tive to USPC [192].
Recommendation 55
Ultrasound-guided percutaneous gallbladder drainage should
be performed transhepatically (LoE 2b, GoR B). Strong consen-
sus (100%).
Percutaneous gastrostomy
!
Introduction
Gastrostomy can be offered when oral food uptake is temporarily
or permanently compromised. Gastrostomy may be used in pa-
tients with neurological disorders (e. g., neurological degenera-
tion) and advanced (oncological) diseases, e. g. in gastrointestinal
stenosis with intractable vomiting where surgical treatment is
not feasible or is declined. The endoscopic approach (percuta-
neous endoscopic gastrostomy, PEG) with the “pull” technique is
the most common technique.
Image-guided percutaneous gastrostomy (without endo-
scopic access)
The percutaneous approach (image-guided percutaneous gas-
trostomy, PG) can be performed under fluoroscopy (radiological-
ly inserted gastrostomy, RIG) or US guidance (USPG).
US guidance in experienced hands allows the identification of the
position of (a) the stomach, (b) the liver, and (c) inmost instances,
the transverse colon. Usually the stomach is filledwith water by a
nasogastric tube, but if US is used to assist endoscopy, air disten-
sion is sufficient.
US may be used in the following situations:
▶ In cases of anticipated difficulty locating the stomach (scars,
advanced gastric cancer, obesity, surgically altered stomach
anatomy).
▶ In endoscopic approach when trans-illumination fails.
▶ In cases without access to the upper gastrointestinal tract
(complete esophageal obstruction).
Recommendation 56
In cases in which conventional endoscopically guided gastric
puncture fails, ultrasound-assisted gastric puncture may make
it possible to accomplish percutaneous gastrostomy (LoE 4,
GoR C). Broad agreement (76%).
Recommendation 57
When placing of a nasogastric tube is not possible, the stom-
ach can be punctured under ultrasound guidance and disten-
ded with air or water to facilitate percutaneous image-guided
gastrostomy (LoE 4, GoR C). Broad agreement (86%).
Antibiotic prophylaxis is mandatory for PEG using the pull tech-
nique for prevention of peristomal infection. For introducer tech-
niques, antibiotic prophylaxis is not necessary. The database for
antibiotic prophylaxis in PEG is comprehensive [284]. There is
data for RIG showing no wound infections [285].
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Percutaneous nephrostomy
!
Introduction
Percutaneous nephrostomy (PCN) remains the procedure of choice
for temporary drainage of the obstructed collecting system when
the transureteral (or retrograde) approach is not indicated or fea-
sible [286, 287]. PCN is also used for urinary diversion and to gain
access to the urinary tract for subsequent interventional urologic
procedures. PCN can be successfully performed in 95–98% of pa-
tients who have a dilated renal collecting system [250].
Indications and contraindications
Indications
PCN may be performed for diagnostic or therapeutic purposes
[288, 289].
▶ Relief of urinary obstruction related to malignancy, urinary
stones or iatrogenic causes [289].
▶ Pyonephrosis and obstructive acute pyelonephritis.
▶ Urinary diversion in patients with urinary fistula, leakage or
hemorrhagic cystitis [290, 291].
▶ Access for endourologic procedures, such as nephrolithotomy
and removal of urinary stones, dilation or stenting of a ureteral
stricture [288].
▶ Diagnostic testing, such as antegrade pyelography, ureteral
perfusion (Whitaker test) [290].
▶ Specific situations, e. g., uroenteric diversion.
▶ Treatment of urolithiasis in transplanted kidneys and external
malignant obstruction [292–295].
Contraindications
There is no absolute contraindication for PCN, but the benefits
and risksmust beweighed for each individual [288, 289]. Relative
contraindications are:
▶ Renal vascular malformations such as an arterial aneurysm
[290],
▶ Severe life-threatening electrolyte imbalances such as hyper-
kalemia, or severe metabolic acidosis [288],
▶ Severe coagulopathy [296].
Imaging modalities
The optimal imaging methods to guide PCN vary at individual
centers. The procedure can be performed with the guidance of
fluoroscopy, US, CT, and various combinations of those tech-
niques [297–299].
Ultrasound guidance
US-guided puncture of the collecting system with subsequent
placement of the drainage tube under fluoroscopic control is re-
garded as the standard technique for PCN [290, 300, 301]. US is
helpful to identify the most appropriate calyx for puncture and
the presence of stones or blood clots or other intraluminal filling
defects and to avoid damage to surrounding organs [302]. In ad-
dition, it is an ideal method for patient follow-up [302].
Recommendation 58
Percutaneous nephrostomy can be effectively performed under
ultrasound guidance (LoE 2b, GoR B). Strong consensus (100%).
Injection of US contrast agents via a needle or catheter can also
confirm whether the needle or PCN catheter have been correctly
inserted in the renal pelvis, with reduction in radiation exposure
which may be especially important in the first trimester of preg-
nancy [303]. Fluoroscopy is recommended to determine the posi-
tion of the needle and guidewire. The catheter can be visualized
by injecting diluted US contrast agent.
Technical aspects and indications
Methods
Positioning
The risk of adjacent organ injury during percutaneous nephros-
tomy is minimized when the nephrostomy is inserted below the
12th rib. Attempts should be made to achieve catheter placement
through a calyx, particularly if percutaneous nephrolithotomy or
other large-bore catheter placement is considered [290].
Seldinger or trocar technique
US-guided PCN tube placement has a success rate of 92–94%
[304, 305]. The trocar and Seldinger techniques are equally effec-
tive [306].
Size
A 6–10F catheter is recommended for PCN. If the collecting sys-
tem is punctured for further procedures (e. g., tumor or stone re-
moval), a larger catheter may be considered (14–22F).
Recommendation 59
In percutaneous nephrostomy, access via the posterior-infer-
ior calyces should be attempted to reduce the risk of pleural
and vascular injury (LoE 5, GoR D). Strong consensus (100%).
Post-procedure catheter management and patient care
Vital signs should be monitored during initial recovery (> 24
hours) [288]. Urinary output should be charted. Urine will be
blood-tinged initially but prolonged hematuria (> 24–48 hours)
should serve as an alert to persistent bleeding from vascular in-
jury [288, 307]. Long-term indwelling catheters should be chan-
ged every 4–6 weeks [250].
Complications
The incidence of major complications ranges from 0–8% [286,
299, 308, 309]. Minor complications occur in 2–38% [286, 299,
308, 309].
Suprapubic puncture of the bladder
!
Introduction
Suprapubic puncture of the bladder is a safe and reliablemethod to
drain the bladder, while avoiding urethral catheterization [310].
US guidance improves the success rate [311–314].
US is recommended to assess the position and volume of the blad-
der, and to avoid the inadvertent puncture of other structures [315,
316].
Recommendation 60
Puncture and drainage of the urinary bladder should be per-
formed under ultrasound guidance (LoE 1b, GoR B). Strong con-
sensus (100%).
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Main indications
Suprapubic puncture of the bladder is indicated in pathological
conditions of the bladder, prostate or urethra that require tem-
porary or permanent drainage of the bladder when urethral ca-
theterization is not possible or is contraindicated.
Contraindications to the percutaneous US-guided
procedure
▶ Absence of visualization of the bladder on US.
▶ Uncorrected coagulopathy.
▶ Other relative contraindications are those secondary to com-
plex anatomy due to congenital disorders, habitus, previous
surgery or infiltrative pelvic cancer.
Materials and technical problems
The procedure is performed under sterile conditions after the ad-
ministration of local anesthesia. Sedation may be useful in select
cases. The position and volume of the bladder are identified by
US and US is used for real-time guidance of the percutaneous
puncture [315, 316]. Catheters are placed by either the Seldinger
or the trocar technique, with dilation of the percutaneous track
when necessary. Catheters of 10F are large enough to relieve
acute urinary retention. Large catheters (> 16F) are recommen-
ded in patients who require prolonged drainage of the bladder
in circumstances such as bladder rupture or complicated urethral
stricture [310].
Complications
US guidance can decrease the complication rate of suprapubic
puncture [310, 314, 317]. Major complications are rare and in-
clude perforation of intestinal loops [318]. Minor complications
include pain, infection, hemorrhage, blockage, hematuria and
catheter misplacement, all of which are less common when US
guidance is performed [314, 317, 319].
Palliative care
!
Palliative care patients often have alterations in locoregional
anatomy, vascular patterns and coagulation factors. Therefore,
for any invasive procedure it is recommended to consider US gui-
dance to improve safety and help minimize complications and
patient discomfort. There are no contraindications of US-guided
procedures in palliative care [320]. The management of cancer
complications indicates potential roles for home-performed US
and US-guided procedures at the end of life [321].
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